| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Heyman Richard A. is a Director at Oric Pharmaceuticals, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 0 buys and 16 sells.
Estimated insider holdings value: $2.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell | 6,700 | $12.00 | $80,430.82 | -2.6% | - | - | |
| Jan 9, 2026 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 13,920 | $25.02 | $348,280.95 | -14.8% | +75.3% | - | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,570 | $30.00 | $47,104.03 | -1.0% | -24.2% | -26.2% | |
| Oct 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $27.67 | $35,143.31 | -1.0% | -20.7% | -21.9% | |
| Oct 4, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 2,825 | $27.51 | $77,703.60 | -2.2% | -13.2% | -28.8% | |
| Oct 1, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 518 | $27.54 | $14,264.32 | -0.4% | -13.9% | -23.8% | |
| Sep 16, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $22.41 | $28,458.16 | -1.0% | +5.3% | -17.6% | |
| Aug 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $23.25 | $29,526.20 | -0.5% | +8.5% | -14.9% | |
| Jul 31, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 2,351 | $27.50 | $64,662.54 | -1.5% | +8.1% | -28.7% | |
| Jul 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $24.80 | $31,496.76 | -0.9% | +10.6% | -13.7% |